List of works - Begoña Comin-Anduix

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

scientific article

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

scientific article published on 3 October 2005

Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice

scientific article published on 13 August 2005

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model

scientific article published on July 2008

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

scientific article

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

scientific article published on 21 February 2018

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors

scientific article

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays

scientific article

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

scientific article published on 29 September 2009

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

scientific article published on May 2008

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

scientific article published on 20 April 2010

Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function

scientific article

Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer

scientific article published on 23 February 2018

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

scientific article published on April 2006

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

article published in 2018

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

scientific article published on March 2015

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

scientific article

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses

scientific article

Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: a new strategy for antitumor drug development

scientific article published in January 2002

Metabolic control analysis in drug discovery and disease

scientific article

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

scientific article (publication date: 15 September 2010)

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

scientific article published on 13 July 2016

Natural killer T cells in advanced melanoma patients treated with tremelimumab

scientific article

PD-1 Blockade Expands Intratumoral Memory T Cells

scientific article published on 19 January 2016

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

scientific article published on 27 August 2013

Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping

scientific article

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

scientific article published on 30 November 2016

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

scientific article published on 2 September 2016

The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy

scientific article

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

scientific article

Tremelimumab: research and clinical development

scientific article

List of works by Begoña Comin-Anduix

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice

CD4+CD25- T cells transduced to express MHC class I-restricted epitope-specific TCR synthesize Th1 cytokines and exhibit MHC class I-restricted cytolytic effector function in a human melanoma model

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors

Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function

Focal Irradiation And Systemic Transforming Growth Factor β Blockade in Metastatic Breast Cancer

Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses

Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: a new strategy for antitumor drug development

Metabolic control analysis in drug discovery and disease

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Natural killer T cells in advanced melanoma patients treated with tremelimumab

PD-1 Blockade Expands Intratumoral Memory T Cells

PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody

Preparation of peptide-MHC and T-cell receptor dextramers by biotinylated dextran doping

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

Tremelimumab: research and clinical development